The opportunity

Healthy aging is one of the largest, fastest-growing demand pools in consumer health — and the ingredient toolkit serving it hasn't kept up. Precision bioactives close that gap.

  • TAM ~$40B — healthy-aging and gut-health ingredients plus cosmeceutical actives.
  • SAM ~$12B — the premium, clinically-validated, IP-protected segment.
  • SOM ~$3B — premium actives priced for GRAS-backed, clinically-supported positioning.

Why Trilliome

A defensible engine. Teroka — a closed wetlab-and-computational loop — learns how to steer the gut ecosystem through bioactives and their combinations. It produces a proprietary dataset that compounds, not a single lucky compound. Platform →

A layered moat. Patents on composition and use, a favourable EPO opinion on the cognitive indication, trade-secret process, and the data moat. IP →

Real commercial pull, with a path to revenue. 7 signed LOIs — including a top-4 global ingredient company — give a clear conversion path: as each active clears its Self-Affirmed GRAS milestone, signed intent moves toward supply, with first revenue targeted in 2027. Three 2025 industry awards underline the category pull.

Capital-efficient by design. Money goes into IP, evidence, and the engine — not D2C marketing. Pricing steps up as clinical milestones land, so the same kilogram earns more over time.

Optionality that compounds. Each active is one output of a repeatable engine — and every product deepens a proprietary dataset and an evidence base that open new domains and progressively deeper applications as the science matures. The value accrues to the platform, not to any single ingredient.

A team that's done it. Two PhD founders with 18+ years each across biotech, pharma, and nutrition. Company →

Where this goes

Trilliome is a healthcare company that enters through the ingredient layer — because that's the fastest way to put precision bioactives, and real human data, into the market and onto a revenue path. It is the entry point, not the ceiling. The same biology, the same engine, and the same compounding evidence base reach further with every product — into new healthspan domains and progressively deeper health applications as the science matures. We're building for the long arc of healthy aging, not a single ingredient and not a single category.

Stay close

We share regular, candid updates with investors and partners through a private channel. If you're an investor exploring the space, request access — and we'll keep you on the inside of the story.

Request investor updates → Company →

Detailed financials, terms, and the data room are shared directly with qualified investors — not published here.

FAQ

  • Is Trilliome a single-ingredient bet? No — it's a platform (Teroka) with a repeatable engine; TRI-01 and TRI-04 are the first outputs, with more in development.
  • What's the moat? Patents, a favourable EPO opinion, trade-secret process, and a compounding proprietary dataset.
  • What's the traction? 7 signed LOIs (including a top-4 global ingredient company), three 2025 awards, and first revenue targeted in 2027.
  • How do I learn more? Request access to our investor updates; detailed materials are shared directly with qualified investors.